Yuh‐Min Chen

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. · The Lancet · 2021 · 1.4K citations

Oncology, Adjuvant Chemotherapy, Pathology +6

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Teh‐Ying Chou, Chao‐Hua Chiu, Ling‐Hui Li et al. · Clinical Cancer Research · 2005 · 321 citations

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 249 citations

Oncology, Met Amplification, Medicine +10

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Jin Soo Lee, Vera Hirsh, Keunchil Park et al. · Journal of Clinical Oncology · 2012 · 231 citations